Titan Medical Names Surgical Robotics Sales Veteran Chad A. Zaring as its Chief Commercial Officer
08 Julho 2019 - 8:30AM
Business Wire
(July 8, 2019) – Titan Medical Inc. (“Titan” or the
“Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company
focused on the design, development and commercialization of a
robotic surgical system for application in minimally invasive
surgery (“MIS”), announces that Chad A. Zaring has joined the
Company as chief commercial officer, a new position. Mr. Zaring has
deep experience developing and executing commercial strategies and
driving sales for leading surgical robotics companies and will be
responsible for the launch of Titan’s single-port robotic surgery
system following receipt of regulatory clearances. He will report
to David McNally, Titan’s chief executive officer.
Mr. Zaring joins Titan from Medtronic, where since September
2017 he was vice president robotics, imaging and navigation. Prior
to Medtronic, he was with Mazor Robotics from May 2015 through the
initiation of a Global Distribution Agreement in September 2017
that led to its subsequent acquisition by Medtronic. As vice
president, national accounts and later vice president, U.S. sales,
he developed the capital sales teams, established new sales
channels and consistently exceeded sales goals. Earlier in his
career, from 2004 to April 2015 Mr. Zaring held positions of
increasing responsibility at Intuitive Surgical, and was a member
of the leadership team that executed early and mid-stage adoption
of their robotic surgery system across multiple surgical
disciplines.
“Chad is the ideal professional to lead the commercialization of
our single-port robotic surgical system, and we are thrilled he has
chosen to join Titan Medical,” said Mr. McNally. “The timing
couldn’t be better. We are at an inflection point in our company’s
development as we prepare for successful execution of preclinical
and clinical studies that will permit us to file for regulatory
clearances both in the U.S. and the EU by the end of the year. We
look forward to having such a talented and broadly experienced
individual as Chad execute our sales strategy and further
strengthen our in-house robotic commercial launch expertise.”
“I am excited to be joining Titan Medical and to advance my
passion of introducing disruptive and life-changing technology,
working to commercialize an innovative single-port robotic surgical
system,” said Mr. Zaring. “I believe that single-port robotic
surgery will be the next frontier in several surgical disciplines.
I am committed to delivering on Titan’s vision of single-port
robotic surgery with the highest standards and with relentless
focus on our customers who will help us drive technology adoption.
Titan will make an important contribution to patient health while
addressing surgeon desires and filling a significant gap in the
market landscape. Titan has already set a thoughtful, early
commercial plan by initially targeting benign gynecologic
indications and subsequently adding more applications over
time.”
Mr. Zaring began his career at Merrill Lynch in 1999 as a
financial sales consultant. He later held sales positions at Merck
and Co. and at Ethicon Endo-Surgery, a Johnson & Johnson
company. He holds a BA degree in biology from Juanita College in
Huntington, Penn.
About Titan Medical Inc.
Titan Medical Inc. is focused on computer-assisted robotic
surgical technologies for application in MIS. The Company is
developing a single-port robotic surgical system comprised of a
surgeon-controlled patient cart that includes a 3D high-definition
vision system and multi-articulating instruments for performing MIS
procedures, and a surgeon workstation that provides an advanced
ergonomic interface to the patient cart and a 3D endoscopic view
inside the patient’s body. Titan intends to initially pursue
gynecologic surgical indications for use of its single-port robotic
surgical system.
For more information, please visit the Company’s website at
www.titanmedicalinc.com.
Forward-Looking Statements
This news release contains “forward-looking statements” which
reflect the current expectations of management of the Company’s
future growth, results of operations, performance and business
prospects and opportunities. Wherever possible, words such as
“may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”,
“expect”, “intend”, “estimate”, “potential for” and similar
expressions have been used to identify these forward-looking
statements. These statements reflect management’s current beliefs
with respect to future events and are based on information
currently available to management. Forward-looking statements
involve significant risks, uncertainties and assumptions. Many
factors could cause the Company’s actual results, performance or
achievements to be materially different from any future results,
performance or achievements that may be expressed or implied by
such forward-looking statements, including, without limitation,
those listed in the “Risk Factors” section of the Company’s Annual
Information Form dated March 29, 2019 (which may be viewed at
www.sedar.com). Should one or more of these risks or uncertainties
materialize, or should assumptions underlying the forward-looking
statements prove incorrect, actual results, performance, or
achievements may vary materially from those expressed or implied by
the forward-looking statements contained in this news release.
These factors should be considered carefully, and prospective
investors should not place undue reliance on the forward-looking
statements. Although the forward-looking statements contained in
the news release are based upon what management currently believes
to be reasonable assumptions, the Company cannot assure prospective
investors that actual results, performance or achievements will be
consistent with these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190708005105/en/
LHA Investor Relations Kim Sutton Golodetz (212) 838-3777
kgolodetz@lhai.com or Bruce Voss (310) 691-7100 bvoss@lhai.com
Titan Medical (NASDAQ:TMDI)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Titan Medical (NASDAQ:TMDI)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024